LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.

• LIR Life Sciences Corp. (SKNY) announced a Technology Development Collaboration Agreement with Resilience BioSciences Inc. (RBI) on April 20, 2026.
• The agreement utilizes RBI's facilities at the adMare BioInnovations site (UBC) for early-stage experimental work including ex vivo porcine skin and formulation studies.
• Financial terms require LIR to pay RBI $5,000 per month for an initial six-month term ($30,000 total).
• This follows a series of R&D announcements from late 2025 through early 2026, including the acquisition completion in November 2025 and patent filings in December.
• The collaboration focuses on expanding preclinical research activities for their transdermal delivery platform targeting GLP/GIP-based obesity therapies.

• Incremental Nature: The $30,000 commitment is negligible relative to the company's recent financing ($1.07M in Oct/Nov 2025) and previous R&D spend (Neuland Phase 1 at $230,000). It does not materially alter the capital structure or cash runway significantly.
• Market Context: The stock price has declined approximately 78% from its January peak ($2.35) to current levels ($0.50), despite a stream of positive news including patent filings and interim preclinical results in January. This indicates market skepticism regarding the value of these milestones or concerns over dilution/cash burn.
• Expectation Alignment: The collaboration is consistent with previous announcements regarding facility usage (ex vivo porcine skin study design was announced Jan 22, 2026). It confirms execution rather than introducing new strategic pivots.
• Sentiment Divergence: Given the severe price deterioration following "positive" news in Q1 2026, this announcement is unlikely to reverse the negative sentiment trend without a significant clinical or commercial catalyst.

• Company: LIR Life Sciences Corp. (formerly Blackbird Critical Metals Corp.).
• Flagship Project: Transdermal delivery platform utilizing Cell-Penetrating Peptides (CPP) for needle-free administration of GLP/GIP-based obesity therapies.
• Development Stage: Preclinical/Early R&D.
  • Completed design of ex vivo porcine skin study (Jan 2026).
  • Launched comparative animal studies for second-generation GLP/GIP therapies (Jan 2026).
  • Filed provisional patent application for needle-free delivery system (Dec 2025).
• Strategic Focus: Expanding the platform to deliver large therapeutic molecules (up to ~150 kDa) through the skin, targeting obesity and metabolic disorders.